Incidence of neuropsychiatric adverse events in influenza patients treated with oseltamivir or no antiviral treatment

International Journal of Clinical Practice

Volumn 63, Issue 4, 2009, Pages 596-605

  Smith, J R ^a,b   Sacks, S ^c  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR;

ADOLESCENT; ADULT; ARTICLE; BILLING AND CLAIMS; CONDUCT DISORDER; DRUG TOLERABILITY; EPILEPSY; FEMALE; HUMAN; INCIDENCE; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MOOD DISORDER; NEUROSIS; ORGANIC BRAIN SYNDROME; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SCORING SYSTEM; SLEEP DISORDER; TREATMENT OUTCOME; VISUAL DISORDER;

ADOLESCENT; ADULT; AGE FACTORS; ANTIVIRAL AGENTS; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; INCIDENCE; INFLUENZA, HUMAN; MALE; MENTAL DISORDERS; OSELTAMIVIR; UNITED STATES; YOUNG ADULT;

EID: 62549130251     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02010.x     Document Type: Article

References (14)

1. Toovey S, Rayner C, Prinssen E et al. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf 2008 31 : 1097 114.
2. Nordstrom BL, Zhu S, Smith JR. Reduction of influenza complications following oseltamivir use. Proceedings and abstracts of the Second European Influenza Conference (St Julian's, Malta) European Scientific Working Group on Influenza, 11-14 September 2005 (Abstract S18-2).
3. McAfee AT, Ming EE, Seeger JD et al. The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy. Pharmacoepidemiol Drug Saf 2006 15 : 444 53.
4. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983 70 : 41 55.
5. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984 79 : 516 24.
6. Connors AF Jr., Speroff T, Dawson NV et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. JAMA 1996 276 : 889 97.
7. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol 1999 150 : 327 33.
8. Wang J, Donnan PT. Propensity score methods in drug safety studies: practice, strengths and limitations. Pharmacoepidemiol Drug Saf 2001 10 : 341 4.
9. Ayanian JZ, Landrum MB, Guadagnoli E, Gaccione P. Specialty of ambulatory care physicians and mortality among elderly patients after myocardial infarction. N Engl J Med 2002 347 : 1678 86.
10. Seeger JD, Walker AM, Williams PL, Saperia GM, Sacks FM. A propensity score-matched cohort study of the effect of statins, mainly fluvastatin, on the occurrence of acute myocardial infarction. Am J Cardiol 2003 92 : 1447 51.
11. Seeger JD, Williams PL, Walker AM. An application of propensity score matching using claims data. Pharmacoepidemiol Drug Saf 2005 14 : 465 76.
12. Shi D, Yang J, Yang D et al. Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J Pharmacol Exp Ther 2006 319 : 1477 84.
13. Charasson V, Bellott R, Meynard D et al. Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38. Clin Pharmacol Ther 2004 76 : 528 35.
14. Tanimoto K, Kaneyasu M, Shimokuni T et al. Human carboxylesterase 1A2 expressed from carboxylesterase 1A1 and 1A2 genes is a potent predictor of CPT-11 cytotoxicity in vitro. Pharmacogenet Genomics 2007 17 : 1 10.